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Hamid R Noori* and Rainer SpanagelThe legal landscape for animal experimentation is rap-
idly changing. Progress in global regulatory frameworks
to improve the protection of animals already has signifi-
cant implications well beyond academic research. Par-
ticularly, the European Union Directives Directive 2010/
63/EU 2010 on the protection of animals used for scien-
tific purposes, and Cosmetics Directive 76/768/EEC
1976, a complete ban on the use of animals for cosmetic
testing in 2013, impose strong constraints on academia
and industry. Hence there is a strong need to improve
the welfare of animals, fortify the three R’s principles
(Replace, Reduce and Refine use of animals) in EU legis-
lation, and provide alternative approaches for animal
research and the testing of new cosmetics. The new reg-
ulations are by no means an exclusive European affaire,
as they have been reinforced globally by bi- and multi-
lateral cooperations.
Therefore, these new regulations will ultimately re-
shape our way of thinking about basic and preclinical
experimental design, by not only limiting the sample size
of experiments, but also adding critical restrictions on
procedures that require alternative, quantitatively-defined
frameworks for experimental setups and analyses. While
the three R’s challenge traditional concepts in animal stud-
ies, which equate an increase in sample size with an
improvement in the robustness of experimental results,
they provide a great chance for in silico approaches (Noori
and Spanagel 2013) to shine.
Ligand- and structure-based virtual screening proce-
dures for drug discovery (Rester 2008), computational
pharmacokinetics (Bois 2013), in silico screening proce-
dures to investigate systemic drug effects (Noori and
Jäger 2010; Noori et al. 2012a), mathematically-based
optimal experimental design (Fedorov et al. 2002) and
novel biostatistical approaches (Beery and Zucker 2011;
Noori et al. 2012b) not only bear the potential to im-
prove animal experiments, but can also reduce the* Correspondence: hamid.noori@zi-mannheim.de
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reproduction in any medium, provided the orignumber of animals used by eliminating unnecessary test-
ing (e.g., via meta-analysis studies).
In Silico Pharmacology provides an optimal electronic
platform for studies in these fields, and through emphasis
on the three R’s intends to assist animal researchers in
overcoming present and future challenges, contributing to
a modernization of their research concepts. In particular,
by being indexed in the largest database of biomedical ar-
ticles established by the US National Library of Medicine
(PubmedCentral: http://www.ncbi.nlm.nih.gov/pmc/jour-
nals/2586/), it has begun to bring its computer-based pub-
lications closer to end-user experimentalist readership and
facilitate communication in the interface area of dry- and
wet-laboratories.
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